Cargando…
Prenatal Screening Using Maternal Markers
Maternal markers are widely used to screen for fetal neural tube defects (NTDs), chromosomal abnormalities and cardiac defects. Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia. The methods initially developed for NTDs using a single marker ha...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449694/ https://www.ncbi.nlm.nih.gov/pubmed/26237388 http://dx.doi.org/10.3390/jcm3020504 |
_version_ | 1782373902321713152 |
---|---|
author | Cuckle, Howard |
author_facet | Cuckle, Howard |
author_sort | Cuckle, Howard |
collection | PubMed |
description | Maternal markers are widely used to screen for fetal neural tube defects (NTDs), chromosomal abnormalities and cardiac defects. Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia. The methods initially developed for NTDs using a single marker have since been built upon to develop high performance multi-maker tests for chromosomal abnormalities. Although cell-free DNA testing is still too expensive to be considered for routine application in public health settings, it can be cost-effective when used in combination with existing multi-maker marker tests. The established screening methods can be readily applied in the first trimester to identify pregnancies at high risk of pre-eclampsia and offer prevention though aspirin treatment. Prenatal screening for fragile X syndrome might be adopted more widely if the test was to be framed as a form of maternal marker screening. |
format | Online Article Text |
id | pubmed-4449694 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-44496942015-07-28 Prenatal Screening Using Maternal Markers Cuckle, Howard J Clin Med Review Maternal markers are widely used to screen for fetal neural tube defects (NTDs), chromosomal abnormalities and cardiac defects. Some are beginning to broaden prenatal screening to include pregnancy complications such as pre-eclampsia. The methods initially developed for NTDs using a single marker have since been built upon to develop high performance multi-maker tests for chromosomal abnormalities. Although cell-free DNA testing is still too expensive to be considered for routine application in public health settings, it can be cost-effective when used in combination with existing multi-maker marker tests. The established screening methods can be readily applied in the first trimester to identify pregnancies at high risk of pre-eclampsia and offer prevention though aspirin treatment. Prenatal screening for fragile X syndrome might be adopted more widely if the test was to be framed as a form of maternal marker screening. MDPI 2014-05-09 /pmc/articles/PMC4449694/ /pubmed/26237388 http://dx.doi.org/10.3390/jcm3020504 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Cuckle, Howard Prenatal Screening Using Maternal Markers |
title | Prenatal Screening Using Maternal Markers |
title_full | Prenatal Screening Using Maternal Markers |
title_fullStr | Prenatal Screening Using Maternal Markers |
title_full_unstemmed | Prenatal Screening Using Maternal Markers |
title_short | Prenatal Screening Using Maternal Markers |
title_sort | prenatal screening using maternal markers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449694/ https://www.ncbi.nlm.nih.gov/pubmed/26237388 http://dx.doi.org/10.3390/jcm3020504 |
work_keys_str_mv | AT cucklehoward prenatalscreeningusingmaternalmarkers |